New-onset diabetes mellitus after renal transplantation

Abstract

Background and Aim. Diabetes mellitus is a very common metabolic disease with a rising incidence. It is both a leading cause of chronic renal disease and one of the most serious comorbidities in renal transplant recipients. New-onset diabetes after renal transplantation (NODAT) is associated with poor graft function, higher rates of cardiovascular complications and a poor prognosis. The aim of this paper is to review current knowledge of NODAT including risk factors, diagnosis and management. Methods. A MEDLINE search was performed to retrieve both original and review articles addressing the epidemiology, risk factors, screening and management of NODAT. We also focused on microRNAs as potential biomarkers of NODAT. Results and Conclusion. Understanding the risk factors (both modifiable-e.g. obesity, viruses, and unmodifiable-e.g. age, genetics) may help reduce the incidence and impact of NODAT using pre-and post-transplant management. This can lead to better long-term graft function and general transplant success.

Progress of new-onset diabetes after liver and kidney transplantation

“…PTDM severely affects the quality of life and long-term survival of kidney transplant recipients ( 36 – 39 ), and its occurrence is caused by multiple factors. Studies have shown that age, BMI, preoperative hyperglycemia, genetic factors, acute rejection and the use of glucocorticoids are independent risk factors for PTDM ( 40 – 44 ). Through PTDM-related studies, it was found that the survival rate of recipients without PTDM after surgery was 98%, while that of recipients with PTDM was only 83%.…”

Influencia del polimorfismo de CYP3A4 y CYP3A5 en la farmacocinética de tacrolimus en receptores de trasplante renal. Revisión narrativa

“…La diabetes de nueva aparición después del trasplante (NODAT), presenta un reto importante ya que es un efecto adverso, que pone en riesgo en la supervivencia del injerto (Zolota et al, 2018). Se relaciona con tasas altas de complicaciones cardiovascular, y una pobre prognosis para el paciente (Goldmannova et al, 2016).…”